Veracyte stock crashed almost 40% early Thursday after the company reset growth expectations for its prostate cancer tissue test, Decipher. The post Veracyte Crashes Almost 40% On Seismic Shift For Its Best-Selling Test appeared first on Investor's Business Daily.
CryptoAlerta — análise de criptomoedas e mercado em tempo real